Market Overview

Myriad Genetics Reports myRisk Cancer Test Improves Colon Cancer Testing by 60%

Related MYGN
A Closer Look At 5 Heavily Shorted Stocks
Study Shows Prolaris Could Save Healthcare System $6B Over 10 Yrs.

Myriad Genetics, Inc. (Nasdaq: MYGN) today announced new clinical data from a study with myRisk Hereditary Cancer, a 25-gene hereditary cancer panel, that showed a 60 percent increase in mutations detected in cancer predisposition genes in patients with a prior history of colon cancer and/or polyps. Myriad is presenting this clinical study and data from four other studies this week at the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA) Annual Meeting in Anaheim, Calif.

Patients with a family history of colon cancer also are vulnerable to other cancers including breast, ovarian, endometrial and stomach cancer. The detection of individuals with mutations associated with hereditary colon cancer greatly increases the chances of successful medical management in those at-risk individuals, which will save lives and reduce the downstream healthcare costs. Also, once a patient has been identified as carrying a deleterious mutation that patient's family members can be tested to determine if they have an increased risk of cancer.

Posted-In: News

 

Related Articles (MYGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters